Targets of aberrant hypermethylation identified in myeloid leukemia

08-14-2006

According to recent research from Germany, genome-wide profiling of CpG methylation identifies novel targets of aberrant hypermethylation in myeloid leukemia.

"The methylation of CpG islands is associated with transcriptional repression and, in cancer, leads to the abnormal silencing of tumor suppressor genes. Because aberrant hyper-methylation may be used as a marker for disease, a sensitive method for the global detection of DNA methylation events is of particular importance.

"We describe a novel and robust technique, called methyl-CpG immunoprecipitation, which allows the unbiased genome-wide profiling of CpG methylation in limited DNA samples," wrote C. Gebhard and colleagues, University Hospital.

"The approach is based on a recombinant, antibody-like protein that efficiently binds native CpG-methylated DNA. In combination with CpG island microarrays, the technique was used to identify >100 genes with aberrantly methylated CpG islands in three myeloid leukemia cell lines.

"Interestingly, within all hypermethylation targets, genes involved in transcriptional regulation were significantly overrepresented. More than half of the identified genes were absent in microarray expression studies in either leukemia or normal monocytes, indicating that hypermethylation in cancer may be largely independent of the transcriptional status of the affected gene," reported the authors.

"Most individually tested genes were also hypermethylated in primary blast cells from acute myeloid leukemia patients, suggesting that our approach can identify novel potential disease markers," wrote the scientists.

They concluded, "The technique may prove useful for genome-wide comparative methylation analysis not only in malignancies."

Gebhard and colleagues published their study in Cancer Research (Genome-wide profiling of CpG methylation identifies novel targets of aberrant hypermethylation in myeloid leukemia. Cancer Res, 2006;66(12):6118-6128).

For additional information, contact M. Rehli, University Hospital, Department of Hematology & Oncology, D-93042 Regensburg, Germany.

Publisher contact information for the journal Cancer Research is: American Association of Cancer Research, 615 Chestnut St., 17th Floor, Philadelphia, PA 19106-4404, USA.

Keywords: Regensburg, Germany, Acute Myeloid Leukemia, DNA Research, Genome Profile, Disease Biomarkers, Microarrays, Hypermethylation.

This article was prepared by Hematology Week editors from staff and other reports. Copyright 2006, Hematology Week via NewsRx.com.